Haverford Trust Company’s Novo Nordisk NVO Stock Holding History

Haverford Trust Company’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,612	Closed	-$1.77M	–	410
2025 Q2	$1.77M	Sell	25,612 -800	-3%	-$54.4K	0.02%	188
2025 Q1	$1.83M	Sell	26,412 -427	-2%	-$35.3K	0.02%	177
2024 Q4	$2.31M	Buy	26,839 +61	+0.2%	+$6.6K	0.02%	165
2024 Q3	$3.19M	Sell	26,778 -660	-2%	-$88K	0.03%	146
2024 Q2	$3.92M	Buy	27,438 +1,178	+4%	+$156K	0.04%	130
2024 Q1	$3.37M	Hold	26,260	–	–	0.04%	143
2023 Q4	$2.72M	Sell	26,260 -1,422	-5%	-$141K	0.03%	143
2023 Q3	$2.52M	Sell	27,682 -50	-0.2%	-$4.41K	0.03%	140
2023 Q2	$2.24M	Buy	27,732 +428	+2%	+$35K	0.03%	142
2023 Q1	$2.17M	Buy	27,304 +2,384	+10%	+$169K	0.03%	143
2022 Q4	$1.69M	Hold	24,920	–	–	0.02%	152
2022 Q3	$1.24M	Buy	24,920 +1,000	+4%	+$53.6K	0.02%	169
2022 Q2	$1.33M	Sell	23,920 -58	-0.2%	-$3.22K	0.02%	166
2022 Q1	$1.33M	Sell	23,978 -76	-0.3%	-$3.9K	0.02%	177
2021 Q4	$1.35M	Buy	24,054 +76	+0.3%	+$4.12K	0.01%	176
2021 Q3	$1.15M	Buy	23,978 +58	+0.2%	+$2.8K	0.01%	186
2021 Q2	$1M	Buy	23,920 +3,920	+20%	+$152K	0.01%	196
2021 Q1	$674K	Hold	20,000	–	–	0.01%	207
2020 Q4	$699K	Sell	20,000 -1,670	-8%	-$57.7K	0.01%	188
2020 Q3	$752K	Sell	21,670 -58	-0.3%	-$1.93K	0.01%	178
2020 Q2	$711K	Sell	21,728 -32	-0.1%	-$1.02K	0.01%	176
2020 Q1	$655K	Sell	21,760 -1,526	-7%	-$45.4K	0.01%	172
2019 Q4	$674K	Buy	23,286 +668	+3%	+$18.5K	0.01%	192
2019 Q3	$585K	Buy	22,618 +266	+1%	+$6.73K	0.01%	198
2019 Q2	$570K	Sell	22,352 -350	-2%	-$8.65K	0.01%	198
2019 Q1	$594K	Buy	22,702 +892	+4%	+$21.9K	0.01%	192
2018 Q4	$502K	Hold	21,810	–	–	0.01%	203
2018 Q3	$514K	Sell	21,810 -478	-2%	-$11.7K	0.01%	212
2018 Q2	$514K	Sell	22,288 -238	-1%	-$5.66K	0.01%	203
2018 Q1	$555K	Buy	22,526 +478	+2%	+$12.6K	0.01%	194
2017 Q4	$592K	Sell	22,048 -1,450	-6%	-$36.9K	0.01%	181
2017 Q3	$566K	Buy	23,498 +500	+2%	+$11.3K	0.01%	174
2017 Q2	$493K	Sell	22,998 -5,000	-18%	-$101K	0.01%	176
2017 Q1	$480K	Buy	27,998 +58	+0.2%	+$1.01K	0.01%	178
2016 Q4	$501K	Sell	27,940 -400	-1%	-$7.25K	0.01%	170
2016 Q3	$589K	Hold	28,340	–	–	0.01%	163
2016 Q2	$762K	Sell	28,340 -230	-0.8%	-$6.31K	0.02%	147
2016 Q1	$774K	Hold	28,570	–	–	0.02%	145
2015 Q4	$830K	Hold	28,570	–	–	0.02%	141
2015 Q3	$775K	Hold	28,570	–	–	0.02%	137
2015 Q2	$782K	Sell	28,570 -4,092	-13%	-$115K	0.02%	127
2015 Q1	$872K	Sell	32,662 -382	-1%	-$8.8K	0.02%	128
2014 Q4	$699K	Buy	33,044 +230	+0.7%	+$5.14K	0.02%	139
2014 Q3	$781K	Buy	32,814 +474	+1%	+$10.9K	0.02%	125
2014 Q2	$747K	Hold	32,340	–	–	0.02%	126
2014 Q1	$738K	Hold	32,340	–	–	0.02%	119
2013 Q4	$598K	Hold	32,340	–	–	0.02%	158
2013 Q3	$547K	Buy	32,340 +8,910	+38%	+$150K	0.02%	126
2013 Q2	$363K	Buy	+23,430	New	+$390K	0.01%	167

Other funds holding NVO

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Haverford Trust Company's NVO Position: Q3 2025 in Review

Haverford Trust Company sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 25,612 shares — an estimated $1.77M sold.

Haverford Trust Company first reported a position in NVO in Q2 2013 and held it in 49 quarters. The position peaked at $3.92M in Q2 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

Haverford Trust Company reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
Haverford Trust Company sold 25,612 Novo Nordisk shares in Q3 2025, an estimated $1.77M.
Haverford Trust Company first reported a position in Novo Nordisk in Q2 2013 and held it in 49 quarters.
Haverford Trust Company's Novo Nordisk position peaked at $3.92M in Q2 2024.
1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Haverford Trust Company's 13F filing for Q3 2025, filed 14 Nov 2025.